Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of amivantamab plus FOLFIRI versus cetuximab or bevacizumab plus FOLFIRI in previously treated RAS/BRAF wild-type metastatic colorectal cancer
MOH_2024-09-30_013674Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amivantamab in colorectal cancer (CRC) (2 arms), sponsored by Janssen Pharmaceutical. Started Sep 2024; status: recruiting.
02
Drugs
amivantamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on MOH_2024-09-30_013674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-30_013674.